The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1758-9193
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review ; volume:14 ; number:1 ; day:27 ; month:12 ; year:2022 ; pages:1-15 ; date:12.2022
Alzheimer's research & therapy ; 14, Heft 1 (27.12.2022), 1-15, 12.2022

Urheber
Brand, Abby L.
Lawler, Paige E.
Bollinger, James G.
Li, Yan
Schindler, Suzanne E.
Li, Melody
Lopez, Samir
Ovod, Vitaliy
Nakamura, Akinori
Shaw, Leslie M.
Zetterberg, Henrik
Hansson, Oskar
Bateman, Randall J.
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s13195-022-01117-1
URN
urn:nbn:de:101:1-2023030821133749679340
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 11:00 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Brand, Abby L.
  • Lawler, Paige E.
  • Bollinger, James G.
  • Li, Yan
  • Schindler, Suzanne E.
  • Li, Melody
  • Lopez, Samir
  • Ovod, Vitaliy
  • Nakamura, Akinori
  • Shaw, Leslie M.
  • Zetterberg, Henrik
  • Hansson, Oskar
  • Bateman, Randall J.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Fluid biomarkers in Alzheimer’s disease – current concepts

Fluid biomarkers in Alzheimer’s disease – current concepts

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Amyloid blood biomarker detects Alzheimer's disease

Amyloid blood biomarker detects Alzheimer's disease

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based molecular biomarkers for Alzheimer’s disease

The accuracy and robustness of plasma biomarker models for amyloid PET positivity

The accuracy and robustness of plasma biomarker models for amyloid PET positivity

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease

Verbundene Objekte